logo

For the Inventor, By the Inventor

La Chaux-de-Fonds, Switzerland

Swaroop K Vakkalanka

This inventor holds 34 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents, primarily in Kinase Modulators. Top assignees: Rhizen Pharmaceuticals Sa, Incozen Therapeutics Pvt. Ltd., Rhizen Pharmaceuticals Ag. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Swaroop K Vakkalanka. Retrieved from https://idiyas.com/inventor/swaroop-k-vakkalanka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 

% Patents Active = 47.1


Average Co-Inventor Count = 2.4

ph-index = 3

Forward Citations = 41(Granted Patents)


Location History:

  • Hyderabad, IN (2017 - 2021)
  • La Chaux-de-Fonds, CH (2016 - 2024)

Company Filing History:

goldMedal29 out of 51 
 
Rhizen Pharmaceuticals Sa
 patents
silverMedal5 out of 7 
 
Incozen Therapeutics Pvt. Ltd.
 patents
bronzeMedal3 out of 5 
 
Rhizen Pharmaceuticals Ag
 patents
where one patent can have more than one assignee

Years Active: 2016-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Kinase Modulators
PI3K Inhibitors
Pharmaceutical Compositions
Calcium Channel Modulators
Glutaminase Inhibitors
Immunomodulators
Optically Pure Derivatives
Protein Kinase Inhibitors
Anti-Inflammatory Compounds
Respiratory Disorders
Autoimmune Treatments
Selective Inhibitors
34 patents (USPTO):Explore Patents
1. 11858907 - Kinase modulators (2024-01-02),
2. 11478481 - Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals (2022-10-25),
3. 11466006 - Dual selective PI3 delta and gamma kinase inhibitors (2022-10-11),
4. 11103488 - Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide (2021-08-31),
5. 11065236 - Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor (2021-07-20),
6. 11020399 - Intermediates useful in the synthesis of compounds as modulators of protein kinases (2021-06-01),
7. 10981919 - Selective PI3K delta inhibitors (2021-04-20),
8. 10947244 - Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations (2021-03-16),
9. 10851107 - Dual selective P13 delta and gamma kinase inhibitors (2020-12-01),
10. 10668051 - Modulators of calcium release-activated calcium channel (2020-06-02),
11. 10611759 - Glutaminase inhibitors (2020-04-07),
12. 10590129 - 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases (2020-03-17),
13. 10570142 - Selective PI3K delta inhibitors (2020-02-25),
14. 10538501 - Kinase modulators (2020-01-21),
15. 10414773 - Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations (2019-09-17),

Title: Innovations and Contributions of Swaroop K Vakkalanka

Introduction

Swaroop K Vakkalanka, based in La Chaux-de-Fonds, Switzerland, is an accomplished inventor with a remarkable portfolio comprising 34 patents. His work predominantly focuses on the development of pharmaceutical formulations and compounds that show promise in treating various diseases. Vakkalanka’s innovative approach and scientific expertise have significantly contributed to advancements in the field of biotechnology.

Latest Patents

Among his most recent patents, Vakkalanka has introduced PI3K protein kinase modulators. This invention specifies a series of formulas containing these modulators, along with methods of their preparation and applications in treating kinase-mediated diseases. Another notable invention is the process for preparing optically pure 2-(1-hydroxy-alkyl)-chromen-4-one derivatives, which serves as valuable pharmaceutical intermediates. This patent discusses processes for crafting these derivatives and their roles in the pharmaceutical industry, particularly in creating medications.

Career Highlights

Throughout his career, Swaroop K Vakkalanka has worked with various esteemed companies, including Rhizen Pharmaceuticals SA and Incozen Therapeutics Private Limited. His contributions at these institutions demonstrate his commitment to innovation and the practical application of his research, enhancing the pharmaceutical landscape.

Collaborations

Collaboration is key to innovation, and Vakkalanka has teamed up with talented colleagues such as Srikant Viswanadha and Meyyappan Muthuppalaniappan. Together, they have combined their expertise to push boundaries in pharmaceutical research and development, resulting in groundbreaking inventions.

Conclusion

Swaroop K Vakkalanka exemplifies the spirit of innovation within the pharmaceutical industry. His extensive list of patents and collaborations highlights his dedication to improving health outcomes through scientific advancement. As the field continues to evolve, Vakkalanka’s contributions remain a beacon for future inventors and researchers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…